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Abstract: Introduction: Surveillance for hepatocellular carcinoma (HCC) is recommended by national
and international guidelines. However, there are no trial data on whether surveillance improves
clinical outcomes in a UK cirrhosis population of mixed aetiology. Our aim was to determine the
impact of, and adherence to, surveillance on overall survival. Methods: We prospectively collected
data on consecutive patients diagnosed with HCC between January 2009 and December 2015 at two
large UK centres. We assessed outcomes depending on whether they had been entered into an HCC
surveillance programme, and if they had adhered to that. Results: Out of 985 patients diagnosed
with HCC in this study, 40.0% had been enrolled in a surveillance programme. Of these, 76.6%
were adherent with surveillance and 24.4% were not. Adherence to surveillance was significantly
associated with improved overall survival, even when accounting for lead-time bias using different
approaches (HR for 270 days lead-time adjustment 0.64, 0.53 to 0.76, p < 0.001). Conclusions: When
adjusted for lead-time bias, HCC surveillance is associated with improved overall survival; however,
the beneficial effect of surveillance on survival was lower than reported in studies that did not
account fully for lead-time bias.
Keywords: HCC; hepatocellular carcinoma; cirrhosis; surveillance; cancer screening; lead-time
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1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and re-
mains a major public health burden worldwide [1,2]. Major increases have been reported in
HCC incidence in the last 25 years, particularly in Europe and North America [3]. In the UK,
there has been a 63% increase in incidence and 55% increase in mortality from HCC over
the past decade [4,5], which is highest in Scotland [6]. Incidence rates for HCC are projected
to rise by 38% (43% for males and 21% for females) in the UK by 2035, accompanied by a
58% rise in mortality [4].
Cirrhosis is the main risk factor for HCC, with up to a third of patients developing
HCC. Patients with cirrhosis have a 1 to 5.8% risk per year of developing HCC [7], but
regular surveillance may allow early detection and increase access to potentially curative
therapies. Five-year survival rates for early stage HCC is more than 70%, compared with
less than 5% when diagnosed at an advanced stage [8–10]. Most guidelines recommend
surveillance is undertaken by 6-monthly ultrasound (US) scan, which has a sensitivity of 58–
89% and specificity greater than 90%, and some centres also incorporate alpha-fetoprotein
(AFP) measurement [11–15].
Lead-time bias greatly affects studies of interventions which aim to detect cancer early.
When this bias arises, survival time is inflated, making an intervention appear to have
a greater effect than it actually has [16]. Many non-randomised, observational studies
have suggested a survival benefit from HCC surveillance [17,18], but did not investigate
whether adherence to surveillance is associated with survival benefit. The aims of this
study were to estimate the survival of patients diagnosed with HCC who had been entered
into a surveillance programme, and to assess the effect of adherence to the programme
on outcomes.
2. Materials and Methods
2.1. Study Design and Population
Consecutive patients who were diagnosed with HCC in a 7-year period from January
2009 to December 2015 were entered prospectively into this study. These patients were
identified through regional multidisciplinary team meetings (MDTs) in Glasgow and
Edinburgh, the two largest centres in Scotland. There are higher levels of socioeconomic
deprivation in Glasgow than Edinburgh and we took this into account as described in
our modelling process. Results are reported according to Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) and Statistical Analyses and Methods
in the Published Literature (SAMPL) guidelines [19,20]. To establish the denominator of
patients who may have been eligible for inclusion in our study, we extracted the total
number of patients with the ICD code ‘C22.0′ for Hepatocellular Carcinoma from the
Scottish Cancer Registry.
2.2. Inclusion Criteria
The decision to enter a patient with known cirrhosis into a surveillance programme
was made by the responsible Gastroenterologist or regional Hepatologist. The aetiology
of underlying liver disease was determined by the patient’s history (including alcohol in-
take), clinical evaluation, laboratory parameters including viral and autoimmune serology,
genetic testing where appropriate, imaging, and histology when available. The Barcelona
Clinic Liver Cancer (BCLC) staging system was used to evaluate the HCC stage at diagno-
sis [21].
2.3. Outcomes
The primary outcome was overall survival, measured in years from diagnosis of HCC.
Surviving patients were followed up until 1 August 2019.
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2.4. Surveillance Adherence
A pragmatic approach for adherence with surveillance was adopted, with adherence
defined as a US scan performed within a surveillance programme up to 9 months prior to
HCC diagnosis. Based upon enrolment in the surveillance programme and adherence, pa-
tients were considered as never entered into surveillance (no surveillance group) or having
been entered into surveillance. Within the group who were enrolled into surveillance, they
were then considered as having been (1) adherent with surveillance or (2) not-adherent
with surveillance.
2.5. Lead-Time Bias Estimation
Surveillance aims to detect lesions at a pre-symptomatic stage. Patients who have
lesions detected by surveillance, therefore, have the additional survival time from when
lesions are detected to when they become symptomatic and thus, will appear to have better
survival (known as lead-time bias). Three separate approaches were used to account for
the effects of lead-time bias on overall survival using:
2.5.1. Rate of Transition to Symptomatic Disease
This approach estimates the additional follow-up time observed purely as a result of
lead-time in patients with a surveillance-detected cancer. Described by Duffy et al. [22], the
rate of transition is from when a cancer is asymptomatic, but surveillance detectable to a






where t is equal to the survival time from HCC diagnosis observed in a patient with a
surveillance-detected cancer. We used data from studies that estimated the time taken
for screen-detectable HCC to transition to symptomatic disease to be between 70 to
140 days [23,24]. We also tested this for the time specified as being non-adherent to
surveillance (9 months) and for the most extreme values, we could find them in the lit-
erature for cirrhotic disease (1.57 years) and non-cirrhotic disease as the upper bound to
provide a conservative estimate (2.66 years) [25].
2.5.2. Describing Lead-Time Using Tumour Size
Assuming surveillance detects tumours when they are smaller and asymptomatic,
we used the maximum tumour diameter at HCC diagnosis, measured on cross-sectional
imaging (either CT or MRI), to generate a scaled and centred variable describing lead-time.
We then used a gamma distribution model to predict the scaled lead-time estimation for
patients who were not in surveillance, based on the maximum size of their tumours and
their BCLC stage (to account for disease spread in addition to just size alone). The gamma
distribution was used as lead-times are always positive and have skewed distributions.
This variable was then included in models as an interaction term with surveillance group,
as the causal effect of surveillance is dependent on lead-time (i.e., patients with early
asymptomatic lesions have much longer survival times, as a combination of long lead-
times and being in surveillance). We performed this analysis in the Edinburgh cohort, as
tumour size was only collected in this cohort.
2.5.3. Counterfactual Estimation
Given there are situations in the management of HCC where there is no anticancer
therapy provided and no effective therapy for cirrhosis, we hypothesised that if we ob-
served improved survival in the supportive care only group, the difference would be due
to lead-time, rather than due to a survival benefit gained by being in surveillance. We
compared the groups who received supportive care only and using a flexible parametric
survival model, applied the differences to our study population. We term here the addi-
tional survival time for patients with a surveillance-detected cancer E(scf). Using these
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three approaches, we estimated plausible values for the effect of HCC surveillance on
overall survival from the point of HCC diagnosis and the effect of surveillance adherence
within these patient populations.
2.6. Data Handling and Statistical Analysis
Data were summarised using percentages and counts for categorical data, mean aver-
age where continuous data were normally distributed (presented with standard deviation—
SD) and median average where continuous data did not fit the normal distribution (pre-
sented with 25th and 75th centiles). To test for baseline differences across summarised
groups, we used the chi-square test (or Fisher’s exact where appropriate) for categorical
data, Welch’s t-test for continuous normally distributed data, Wilcoxon signed rank test for
non-normal continuous data, or the Kruskal–Wallis test for continuous data where there
were more than two groups. To see whether we could identify predictors of entering and
adhering to surveillance, multilevel regression modelling was used to account for variation
observed across the centres and patient-level characteristics. Patient-level characteristics
were modelled as fixed effects, with centre specified as a random effect. For these models,
variables were selected on the basis they were clinically relevant and were unlikely to be
confounded. Continuous variables were centred or separated into clinically relevant cate-
gories prior to inclusion in models. Final model selection was guided by the minimisation
of the Akaike information criterion (AIC). Effects estimates are represented as odds ratios
(OR) with the corresponding 95% confidence interval (95% CI).
Where missing data for predictor variables were present, multiple imputation by
chained equations was planned to impute these data. Missing data rates were very low,
and imputation was not required.
For survival analyses, as we were modifying the survival times based on our lead-
time bias estimates, we used a flexible parametric model to estimate hazards at a given
time. We specified centre as a random effect variable within this model to account for
centre-level variation. Survival effect estimates are represented as Hazard Ratios (HR) with
the corresponding 95% confidence interval. First order interactions were examined for each
variable entered into every multivariable model and significant interactions retained.
Statistical significance was set at the level of p < 0.05. All statistical analysis was
performed using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria)
using the Tidyverse, flexsurv and finalfit packages.
3. Results
We included 985 patients diagnosed with HCC in the two centres between 1 January
2009 and 31 December 2015 inclusive. From the Scottish Cancer Registry, for the population
covered by the two centres, there were a total number of 1117 incident cases over the same
study time period, giving a case ascertainment rate of 88.18%. Of these 985 patients, 638
(64.8%) were from Centre 1 (Glasgow) and 347 (35.2%) were from Centre 2 (Edinburgh).
Data are shown by centre in Supplementary Table S1).
Missing data in all fields were ≤1%; therefore, no imputation was required. During
the study period between 2009 and 2015, the number of patients diagnosed annually with
HCC rose from 96 to 182.
Table 1 shows the characteristics of the included patients; the median age of the
patients was 69 years (25th centile—61; and 75th centile—77) and 789 (80.1%) patients
were male.
The most common aetiology for underlying liver disease was Alcoholic Liver Disease
(47.9%), followed by Non-alcoholic Fatty Liver Disease (23.7%) and viral hepatitis (21.5%;
see Table 1). There were no changes in the distribution of patient characteristics over time.
Characteristics were similar across centres, with the exception of disease aetiology, where
a greater proportion of patients in Centre 1 had ALD (53.0%, 338/638 in Centre 1 versus
38.6%, 134/347 in Centre 2); and for BCLC stage at HCC diagnosis, where Centre 1 had
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a lower proportion of patients with BCLC Stage 0/A disease (17.1%, 109/638 in Centre 1
versus 41.2%, 143/347 in Centre 2; Supplementary Table S2).
Table 1. Patient characteristics by surveillance adherence group.






Total N (%) 591 (60.0) 92 (9.3) 302 (30.7)
Age at diagnosis 985 0 Median (25th,75th centile) 73.0 (64.5 to 79) 67.0 (60.8 to 73) 64.0 (58 to 71) <0.001
†
Sex 985 0 Female 106 (17.9) 22 (23.9) 68 (22.5) 0.161
Male 485 (82.1) 70 (76.1) 234 (77.5)






(2011 to 2014) 0.007
†
Child–Pugh Stage at
diagnosis 985 0 No Cirrhosis 142 (24.0) 5 (5.4) 10 (3.3) <0.001
A 169 (28.6) 32 (34.8) 150 (49.7) 0.023
B 209 (35.4) 46 (50.0) 114 (37.7)
C 71 (12.0) 9 (9.8) 28 (9.3)
Alcoholic Liver Disease 985 0 No 331 (56.0) 40 (43.5) 142 (47.0) 0.009
Yes 260 (44.0) 52 (56.5) 160 (53.0)
Viral hepatitis 985 0 No 513 (86.8) 68 (73.9) 194 (64.2) <0.001
Yes 78 (13.2) 24 (26.1) 108 (35.8)
Non-alcoholic fatty liver
disease 985 0 No 447 (75.6) 69 (75.0) 236 (78.1) 0.670
Yes 144 (24.4) 23 (25.0) 66 (21.9)
Other 985 0 No 387 (65.5) 69 (75.0) 250 (82.8) <0.001
Yes 204 (34.5) 23 (25.0) 52 (17.2)
All tests are chi-square, except when denoted by † where Kruskal–Wallis tests used. SD—Standard Deviation.
3.1. Enrolment and Adherence to Surveillance
Out of the 985 included patients, 591 (60.0%) had not been enrolled in HCC surveil-
lance, 302 (30.7%) had been enrolled and were adherent with surveillance, and 92 (9.3%)
had been enrolled but were not adherent with surveillance. The overall adherence for
surveillance was 76.6% (302/394). Patients in the surveillance groups were younger than
those not in surveillance, were more likely to have ALD, viral hepatitis or ‘other aetiology’
and had lower Child–Pugh stage at diagnosis of HCC (Table 1). Using multilevel modelling,
female sex, younger age, the presence of alcoholic liver disease, viral hepatitis and NAFLD
were associated with entry into surveillance (Table 2). We found no clinical characteristics
predicted adherence to surveillance (Supplementary Table S3).




Surveillance OR (Univariable) OR (Multilevel)
Age at diagnosis Mean (SD) 70.9 (11.4) 64.8 (9.7) 0.95 (0.94–0.96, p < 0.001) 0.97 (0.95–0.98, p < 0.001)
Sex Female 106 (54.1) 90 (45.9) - -
Male 485 (61.5) 304 (38.5) 0.74 (0.54–1.01, p = 0.059) 0.60 (0.42–0.85, p = 0.004)
Alcoholic Liver Disease No 331 (64.5) 182 (35.5) - -
Yes 260 (55.1) 212 (44.9) 1.48 (1.15–1.92, p = 0.003) 1.75 (1.20–2.55, p = 0.004)
Viral hepatitis No 513 (66.2) 262 (33.8) - -
Yes 78 (37.1) 132 (62.9) 3.31 (2.42–4.56, p < 0.001) 2.35 (1.49–3.69, p < 0.001)
Non-alcoholic fatty
liver disease No 447 (59.4) 305 (40.6) - -
Yes 144 (61.8) 89 (38.2) 0.91 (0.67–1.22, p = 0.520) 1.29 (0.85–1.94, p = 0.231)
Other No 387 (54.8) 319 (45.2) - -
Yes 204 (73.1) 75 (26.9) 0.45 (0.33–0.60, p < 0.001) 0.99 (0.62–1.57, p = 0.963)
SD—Standard Deviation, OR—Odds Ratio.
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3.2. Stage at Diagnosis
Over half the patients in the adherent with surveillance group (52.6%, 159/302) were
diagnosed with BCLC stage 0/A disease, compared to 16.3% (15/92) in the not adherent
group and 13.5% (78/591) in the no surveillance group (p < 0.001; Table 3). In both the
non-adherent to surveillance and not under surveillance groups, disease at presentation
was more advanced. Patients with higher BCLC stages had poorer overall survival, which
was consistent across all surveillance groups (Figure 1).
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Table 3. Stage of disease and subsequent therapy by surveillance adherence group.






Total N (%) 591 (60.0) 92 (9.3) 302 (30.7)
BCLC Stage at diagnosis 985 0 0/A 78 (13.2) 15 (16.3) 159 (52.6) <0.001
B 128 (21.7) 31 (33.7) 68 (22.5)
C 234 (39.6) 28 (30.4) 52 (17.2)
D 151 (25.5) 18 (19.6) 23 (7.6)
AFP level 941 44 <100 299 (50.6) 61 (66.3) 241 (79.8) <0.001
>1000 165 (27.9) 16 (17.4) 16 (5.3)
100–1000 87 (14.7) 10 (10.9) 41 (13.6)
Not known 5 (0.8) 0 (0.0) 0 (0.0)
(Missing) 35 (5.9) 5 (5.4) 4 (1.3)
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Table 3. Cont.






Treatment 983 2 Liver resection 36 (6.1) 4 (4.3) 24 (7.9) <0.001
Liver
transplant 8 (1.4) 3 (3.3) 45 (14.9)
Ablative
therapies 20 (3.4) 9 (9.8) 43 (14.2)
Sorafenib 22 (3.7) 2 (2.2) 7 (2.3)
Supportive
care only 382 (64.6) 47 (51.1) 85 (28.1)
TACE 122 (20.6) 27 (29.3) 97 (32.1)
(Missing) 1 (0.2) 0 (0.0) 1 (0.3)
Treatment type 983 2 Curativetherapy 64 (10.8) 16 (17.4) 112 (37.1) <0.001
Palliative
therapy 144 (24.4) 29 (31.5) 104 (34.4)
Supportive
care only 382 (64.6) 47 (51.1) 85 (28.1)
(Missing) 1 (0.2) 0 (0.0) 1 (0.3)
Treatment intent 983 2 Curative 64 (10.8) 16 (17.4) 112 (37.1) <0.001
Palliative 526 (89.0) 76 (82.6) 189 (62.6)
(Missing) 1 (0.2) 0 (0.0) 1 (0.3)
AFP—Alpha-fetoprotein, BCLC—Barcelona Clinic Liver Cancer, TACE—Transarterial Chemoembolisation. All tests are chi-square.
3.3. Treatment Intent
Patients adherent to surveillance were most likely to receive potentially curative
treatments (37%), compared with those not adherent (17.4%) and those not in surveillance
(10.8%) p < 0.001 (Table 3). When adjusted for potential confounders using a multilevel
logistic regression model (Table 4), surveillance remained significantly associated with
receipt of curative therapy. When BCLC stage was included as an interaction term due to
its impact on receipt of curative therapy, adherence to surveillance remained significantly
associated with the use of curative therapies, regardless of BCLC stage (Table 4).
Table 4. Model for receiving potentially curative therapy.
Dependent:
Treatment Intent Palliative Curative OR (Univariable) OR (Multilevel)
Surveillance group No surveillance/notcompliant 602 (88.3) 80 (11.7) - -
Adherent to
surveillance 189 (62.8) 112 (37.2) 0.73 (0.43–1.24, p = 0.249) 0.67 (0.38–1.20, p = 0.182)
BCLC Stage at
diagnosis 0/A 98 (39.0) 153 (61.0) - -
B 210 (92.9) 16 (7.1) 0.02 (0.01–0.05, p < 0.001) 0.02 (0.01–0.06, p < 0.001)
C 296 (94.3) 18 (5.7) 0.02 (0.01–0.05, p < 0.001) 0.02 (0.01–0.05, p < 0.001)
D 187 (97.4) 5 (2.6) 0.00 (0.00–0.01, p < 0.001) 0.00 (0.00–0.02, p < 0.001)
Age at diagnosis Median (25th to 75thcentile) 71 (63 to 78) 71 (63 to 78) 0.95 (0.93–0.96, p < 0.001) 0.95 (0.92–0.97, p < 0.001)
Sex Female 153 (78.1) 43 (21.9) - -
Male 638 (81.1) 149 (18.9) 0.83 (0.57–1.23, p = 0.343) 1.06 (0.62–1.80, p = 0.829)
Alcoholic Liver
Disease No 406 (79.3) 106 (20.7) - -
Yes 385 (81.7) 86 (18.3) 0.86 (0.62–1.17, p = 0.334) 0.69 (0.40–1.18, p = 0.173)
Child–Pugh Stage No Cirrhosis 130 (83.3) 26 (16.7) - -
A 243 (69.4) 107 (30.6) 2.20 (1.38–3.61, p = 0.001) 0.66 (0.31–1.37, p = 0.264)
B 319 (86.4) 50 (13.6) 0.78 (0.47–1.33, p = 0.354) 0.42 (0.19–0.92, p = 0.029)
C 99 (91.7) 9 (8.3) 0.45 (0.19–0.98, p = 0.054) 0.78 (0.19–3.31, p = 0.739)
Viral hepatitis No 648 (83.8) 125 (16.2) - -
Yes 143 (68.1) 67 (31.9) 2.43 (1.71–3.43, p < 0.001) 0.96 (0.50–1.88, p = 0.913)
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Table 4. Cont.
Dependent:
Treatment Intent Palliative Curative OR (Univariable) OR (Multilevel)
Non-alcoholic fatty
liver disease No 608 (81.1) 142 (18.9) - -
Yes 183 (78.5) 50 (21.5) 1.17 (0.81–1.67, p = 0.396) 1.41 (0.75–2.64, p = 0.288)
Other No 556 (78.9) 149 (21.1) - -
Yes 235 (84.5) 43 (15.5) 0.68 (0.47–0.98, p = 0.044) 1.31 (0.64–2.67, p = 0.459)
Adherent to
surveillance: BCLC B Interaction - - 4.50 (1.41–14.81, p = 0.011) 4.63 (1.41–15.23, p = 0.012)
Adherent to
surveillance: BCLC C Interaction - - 4.85 (1.51–14.90, p = 0.006) 4.46 (1.35–14.72, p = 0.014)
Adherent to





BCLC—Barcelona Clinic Liver Cancer, SD—Standard Deviation, OR —Odds Ratio. Curative therapies are Surgery and Transplant.
3.4. Survival
Median overall survival was 6.0 months in the no surveillance group (25th centile
2.0 months, 75th centile 21.0 months), 10.1 months in the not adherent with surveillance
group (25th centile 2.4 months, 75th centile 25.2 months) and 28.7 months in the adherent
with surveillance group (25th centile 11.4 months, 75th centile 52.0 months). At the time
of data collection, a total of 1881 years of follow-up had been accrued by all patients in
the study. When lead-time bias was not accounted for, adherence with surveillance was
associated with longer survival (Figure 2A). When adjusted for explanatory variables, this
association persisted (Figure 2B).
Child–Pugh grade, increasing age and centre were the only other variables associated
with survival, with cirrhosis of any grade associated with worse survival (Figure 2B and
Table 4).
When using the transition to symptomatic disease method to account for lead-time
bias, adherence to surveillance remained associated with a survival benefit (Figure 2C). As
a sensitivity analysis, we entered further permutations of lead-time (Supplementary Figure
S1, Kaplan–Meier for symptom transition method. A—70 days, B—140 days, C—270 days,
D—1.57 years, E—2.66 years). For all permutations of transition time except 2.66 years
(conservative estimate in methodology as above), a significant association between survival
and adherence to surveillance remained. Patients who were not adherent to surveillance
continued to have a similar survival to those who were not entered into surveillance, up
to and including 140 days adjustment. When adjusted lead-time exceeded 140 days, we
observed worse survival in the not adherent group, supporting the hypothesis that both
lead-time and surveillance group contribute to the total observed effect of surveillance
for HCC.
When we described lead-time as a variable in our model based on tumour size
at presentation in the Edinburgh cohort, we found the beneficial effect of surveillance
adherence on overall survival persisted independent of lead-time (Figure 2D). Patients
with shorter lead-times/larger tumours at HCC diagnosis had shorter survival.
Finally, using the counterfactual approach, adherence to surveillance was not signif-
icantly associated with improved survival, but did not reverse the effect of surveillance
(Figure 2E, Supplementary Figure S2).
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Figure 2. Corrections for lead-time bias. (A) Overall survival by surveillance adherence, without adjustment for lead-time,
(B) flexible parametric survival model for overall survival with no adjustment for lead-time bias, (C) flexible parametric
survival model for overall survival, adjusted for lead-time bias using rate of transition to symptomatic disease method
(270 days), (D) flexible parametric survival model for overall survival, adjusted for lead-time bias using tumour size method,
(E) flexible parametric survival model for overall survival, adjusted for lead-time bias using counterfactual method.
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3.5. Sensitivity Analysis
Patients in surveillance were significantly more likely to receive potentially curative
therapies, even when lead-time bias was accounted for (Figure 3).
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4. Discussion
This study found that in a large patient population undergoing real world surveillance
in the two largest Scottish regions, HCC surveillance was associated with earlier disease
stage at presentation, increased use of therapy with curative intent, and improved overall
survival from diagnosis. However, patients with poor adherence to surveillance had out-
comes similar to those never entered into surveillance. The beneficial effect of surveillance
on overall survival was lower than that reported in many other studies that did not fully
consider lead-time bias.
There is a lack of high-quality, randomised evidence to clarify the best approach
to HCC surveillance based either on outcomes or cost efficiency. Most of the evidence
regarding the effectiveness of HCC surveillance is from observational studies and only two
RCTs have been published, both from China in HBV infected populations [26,27]. One RCT
used both USS and AFP for surveillance and reported a 37% reduction in mortality despite
suboptimal adherence, whereas the other used AFP measurement only and reported no
difference in survival. It is unclear whether the results can be extrapolated to a Western
population with different aetiology of liver disease.
Adherence is a critical factor in determining the effectiveness of a given intervention.
We found that patients with poor surveillance adherence had similar survival to patients
with no surveillance. Indeed, our sensitivity analyses and adjustments for lead-time
bias suggested this group may even have poorer survival. This could be an artefactual
finding arising from our modelling techniques, or it could be that patients who are poorly
adherent may have different behavioural or healthcare-seeking characteristics from the
other groups [28]. The importance of adherence to surveillance should be a key component
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of the initial discussion with a patient who is being considered for entry into an HCC
surveillance programme.
Our study has several strengths. Firstly, the study population was highly annotated
consecutive patients diagnosed with HCC, with cirrhosis of various aetiologies, and in-
cluded referrals from smaller local hospitals. Therefore, our study is likely to represent
a real-world scenario. Much of the current evidence is from areas in the world where
HBV and/or HCV are endemic. It is well described that there are differences in the
clinical characteristics and genetic drivers of HCC arising on a background of viral liver
disease compared with other aetiologies; therefore, our study helps address this area of
uncertainty [29].
We also used a variety of statistical approaches to account for lead-time bias. Most
studies of HCC surveillance rely on a single method using assumptions such as tumour
volume doubling time, which may be unreliable given the heterogeneous nature of HCC
tumours [30]. In addition, by analysis of data from the Scottish Cancer Registry, we
confirmed that we managed to capture 88.18% of all HCC cases from our centres over the
study period.
Our study has several limitations. The data originate from a prospectively collected
observational database. We chose a pragmatic definition of adherence to surveillance
defined as a US scan performed within 9 months prior to HCC diagnosis. However, this
time period has been used by other studies in this field and takes into account potential
organisational delays in coordinating US scans [31,32]. Furthermore, we did not collect
detailed data on number of tumours, size of tumour at diagnosis or details on the presence
portal hypertension. This was to make the study feasible by minimizing the number
of variables to be collected. This meant that we grouped BCLC stage 0 and A together.
Although this could be considered an important distinction, patients in both stages are
eligible for curative therapy and are likely to have the best prognosis. Therefore, we believe
this grouping is unlikely to have had a major effect on our findings.
Given our findings, controversy about the clinical and cost-effectiveness of HCC
surveillance is likely to continue. Estimating the true effect of HCC surveillance on overall
survival would ideally be carried out in a large RCT. However, this would be extremely
challenging due to issues of patient acceptability, controversy around the clinical equipoise
of surveillance, current guidelines recommending surveillance, and potential new develop-
ments in surveillance technologies. These difficulties were underlined when investigators
tested the feasibility of conducting an RCT in 205 patients with liver cirrhosis and 99.5%
of patients declined randomisation, with 88% choosing non-randomised surveillance [33].
The fact that only 37.1% patients adhering to surveillance in our study underwent curative
therapy underlines the limitations of the surveillance investigations and methods that are
currently recommended by most guidelines. This emphasises the importance of finding
new and better surveillance tests that may include biomarkers and abbreviated MRI.
In conclusion, current evidence for HCC surveillance in a population with mixed
causes of cirrhosis is confounded by lead-time bias. We have demonstrated that the
effect size of HCC surveillance on overall survival is smaller than previously described.
Despite this, adherence to surveillance is associated with earlier stage at HCC diagnosis,
increased access to curative therapies, and increased survival. However, patients with poor
adherence to surveillance have outcomes similar to patients never enrolled in surveillance,
which is an important educational point to discuss with patients being entered into a
surveillance programme.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10132770/s1, Figure S1: Kaplan–Meier for symptom transition method. A—70 days,
B—140 days, C—270 days, D—1.57 years, E—2.66 years, Figure S2: Kaplan–Meier plot by surveil-
lance adherence, with adjustment for counterfactual method, Table S1: Characteristics by Centre,
Table S2: Stage of disease by centre and surveillance adherence, Table S3: Predictors of adherence to
surveillance (including centre).
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